ArticleBMC infectious diseases2025
Comprehensive evaluation of NAT+/HBsAg- blood donors: confirmation strategies, serial testing outcomes, and S gene mutations associated with occult HBV infection.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- [Effectiveness of donor selection in a blood bank].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Hepatitis B vaccination in Chinese infants (2002-2006, Guangdong): long-term effectiveness in adulthood and biological features of HBV infection.Frontiers in immunology · 2026Article
- Review
- Prevalence and Implications of Occult Hepatitis B Virus Infection Among Blood Donors in Saudi Arabia: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundS gene mutations may lead to undetectable HBsAg, contributing to occult HBV infection (OBI). Nucleic acid testing (NAT) has been widely implemented to reduce transfusion-transmitted OBI. However, distinguishing between false positives and true OBI among NAT+/HBsAg- donors remains challenging, as these individuals frequently exhibit inconsistent or fluctuating test results. This study aims to improve infection status confirmation and donor management by analyzing detection patterns and investigating S gene mutations.
methodsBlood donors were detected for HBV using individual-NAT and HBsAg enzyme-linked immunosorbent assays. Routine discriminatory test (dHBV), additional three repeated dHBV (3-repeated dHBV), and serological assays were conducted to confirm the infection status of NAT+/HBsAg- donors. Serial NAT results were analyzed to assess temporal fluctuations. S gene mutations related with OBI were identified through molecular characterization and sequencing analysis.
resultsA total of 336,537 blood donors were detected, and 556 (0.16%) NAT+/HBsAg- cases were identified. Among 297 donors undergoing confirmation, 112 (37.71%) were confirmed by routine dHBV, 152 (51.18%) by 3-repeated dHBV, and 43 (14.48%) by multiple serial NATs. In total, 187 donors (62.96%, 187/297) were confirmed HBV-infected, significantly higher than routine dHBV alone (P < 0.01). Among the 187 confirmed HBV-infected donors, only 59 (31.55%) were positive in all four dHBV tests, while 128 (68.45%) showed missed detections, suggesting extremely low viral loads. In serial NAT testing, 83 (73.45%, 83/113) of donors confirmed by dHBV showed no further NAT-positive results, and an average of 5.6 tests was needed to detect one extra positive case. Molecular analysis revealed that OBI samples had more mutations in both the major hydrophilic region (MHR) and non-MHR compared to HBsAg + donors (P < 0.05), with a significantly higher prevalence of the E2G mutation.
conclusionsOBI is a major contributor to inconsistent NAT results. Comprehensive measures, especially repeated testing, are recommended to improve confirmation rates and reduce the risk of re-entry of potentially infectious donors. Additionally, further molecular research on S gene mutations is essential for elucidating OBI mechanisms and enhancing assay sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.